SCHEMBL3972540

SCHEMBL3972540

Nc1ccc(C(N)C2CC2)cc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.38
MAPT P10636 1/20 0.38
KMT2A Q03164 1/20 0.38
RPS6KB1 P23443 3/20 0.36
ALDH1A1 P00352 3/20 0.33
IDO1 P14902 2/20 0.33
CYP3A4 P08684 2/20 0.33
TP53 P04637 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
AKT2 P31751 4/20 0.33
GSK3B P49841 2/20 0.33
SLC6A3 Q01959 1/20 0.31
OPRM1 P35372 2/20 0.31
OPRD1 P41143 2/20 0.31
OPRK1 P41145 2/20 0.31
OPRL1 P41146 2/20 0.31
ALOX15 P16050 2/20 0.31
MAPK1 P28482 1/20 0.31
ACHE P22303 1/20 0.31
CA3 P07451 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3964601 0.91 IDO1 (0.36) MEN1MAPTKMT2ARPS6KB1ALDH1A1
SCHEMBL1821736 0.79 ESR1 (0.41) MEN1MAPTKMT2AALDH1A1IDO1
SCHEMBL16232134 0.79 OPRM1 (0.47) MEN1KMT2ARPS6KB1IDO1TDP1
SCHEMBL2675532 0.79 RPS6KB1 (0.48) RPS6KB1IDO1OPRM1OPRD1OPRK1
SCHEMBL3721733 0.79 OPRM1 (0.41) RPS6KB1ALDH1A1OPRM1OPRD1OPRK1
SCHEMBL16232135 0.79 OPRM1 (0.47) MEN1KMT2ARPS6KB1IDO1TDP1
SCHEMBL1239995 0.79 RPS6KB1 (0.48) RPS6KB1IDO1OPRM1OPRD1OPRK1
SCHEMBL13885596 0.79 ACACB (0.37) RPS6KB1IDO1AKT2GSK3BSLC6A3
SCHEMBL390679 0.79 ADRB2 (0.48) RPS6KB1IDO1TP53TDP1AKT2
SCHEMBL987778 0.79 OPRM1 (0.41) RPS6KB1ALDH1A1OPRM1OPRD1OPRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7563806-B2 Substituted cycloalkyl derivatives, process for the manufacture thereof and use thereof as medicament BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-07-21 US disclosed
US-7423035-B2 Substituted cycloalkyl derivatives, process for the manufacture thereof and use thereof as medicament BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2008-09-09 US disclosed
US-20080146554-A1 Substituted Cycloalkyl Derivatives, Process for the Manufacture thereof and Use thereof as Medicament BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2008-06-19 US disclosed
US-20050261286-A1 Substituted cycloalkyl derivatives, process for the manufacture thereof and use thereof as medicament BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2005-11-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080146554-A1 Substituted Cycloalkyl Derivatives, Process for the Manufacture thereof and Use thereof as Medicament CHRM1, CHRM2, CHRM3 MEN1 4355/4885MAPT 4413/4885KMT2A 3785/4885
US-20050261286-A1 Substituted cycloalkyl derivatives, process for the manufacture thereof and use thereof as medicament CHRM1, CHRM2, CHRM3 MEN1 4355/4885MAPT 4413/4885KMT2A 3785/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.